Celldex Therapeutics (CLDX)
(Delayed Data from NSDQ)
$22.19 USD
+0.21 (0.96%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $22.21 +0.02 (0.09%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Fundamental Charts
About Return on Equity (TTM)
Celldex Therapeutics, Inc.'s return on equity, or ROE, is -23.46% compared to the ROE of the Medical - Biomedical and Genetics industry of -62.65%. While this shows that CLDX has struggled to make solid use of its equity, this metric will vary significantly from industry to industry.
Return on Equity (or ROE) is calculated as income divided by average shareholder equity (past 12 months, including reinvested earnings). The income number is listed on a company's Income Statement. Shareholder Equity (which is the difference between Total Assets and Total Liabilities) can be found on the Balance Sheet.
CLDX 22.19 +0.21(0.96%)
Will CLDX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for CLDX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CLDX
scPharmaceuticals (SCPH) Soars 8.8%: Is Further Upside Left in the Stock?
Xenon Pharmaceuticals (XENE) Up 8.7% Since Last Earnings Report: Can It Continue?
CLDX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Celldex Therapeutics (CLDX) Reports Q1 Loss, Lags Revenue Estimates
Cytokinetics (CYTK) Moves 5.4% Higher: Will This Strength Last?
Celldex Therapeutics (CLDX) Reports Q4 Loss, Lags Revenue Estimates
Other News for CLDX
Interesting CLDX Put And Call Options For September 19th
RBC downgrades Jasper Therapeutics on questions about briquilimab
Celldex Therapeutics’ Promising Phase 2 Study on Eosinophilic Esophagitis
Celldex’s Phase 3 Study on Barzolvolimab: A Potential Game-Changer for Chronic Urticaria
Celldex Therapeutics Advances Phase 2 Study on Barzolvolimab for Prurigo Nodularis